Key Highlights

  • 8.7x relative volume: Varonis Systems (NASDAQ:VRNS) traded 13,974,397 shares on October 16, 2026 per published market data, against an implied average of 1.61 million, own arithmetic. Turnover of USD 682.4 million equals 12.2% of the USD 5.59 billion market value, own arithmetic.
  • 1.9x relative volume: SCWorx (NASDAQ:WORX) rose 56.72% to USD 3.15 on 2,081,698 shares against 549,100 shares outstanding, or 3.79 times the count, own arithmetic. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026.
  • 1.3x relative volume: TNL Mediagene (NASDAQ:TNMG) traded 1,559,824 shares at USD 3.23, down 0.68%, after a 6-K dated October 16, 2026 reported Nasdaq bid-price compliance. The USD 2.5 million stockholders' equity test is due October 30, 2026.
  • 1.3x relative volume: ACV Auctions (NASDAQ:ACVA) traded 5,338,105 shares at USD 10.50, unchanged and equal to the Copart offer. Turnover of USD 56.05 million is 3.1% of the USD 1.78 billion market value, own arithmetic.

Varonis Systems (NASDAQ:VRNS)

Proofpoint, a Thoma Bravo portfolio company, agreed on October 15, 2026 to buy Varonis for USD 49.75 per share in cash, a deal valued at USD 6.3 billion per the company release. Per published market data on October 16, 2026 intraday, the stock traded at USD 48.83, up 2.72%, a USD 0.92 or 1.9% gap to the offer, own arithmetic. The 8.7x relative volume implies an excess of 12.37 million shares over the average, own arithmetic, which is the signature of long-only holders exiting and event-driven funds taking the other side. In an all-cash merger the quote converges on the offer less the time value of money and completion risk. The release gives a 52% premium to the USD 32.71 close of June 22, 2026 and 17% over the USD 42.35 close of September 1, 2026. Per the filing, the break fee is USD 211.7 million, the reverse fee is USD 423.3 million, the termination date is July 15, 2027 and closing is expected in the first half of 2027. The implied prior close of USD 47.54 differs from the USD 47.34 close of October 15 in published market data and is not reconciled.

SCWorx (NASDAQ:WORX)

SCWorx rose 56.72% to USD 3.15 with a 3.48% gap and a 51.44% gain from the open, so most of the rise came after the first trade, own arithmetic. No company-specific catalyst was identified in the filings and releases reviewed through October 16, 2026. Volume of 2,081,698 shares compares with an implied average of 1.10 million, own arithmetic, and turnover of USD 6.56 million equals 379% of the USD 1.73 million market value, own arithmetic. The 8-K for the September 16, 2026 private placement shows 350,000 shares and 350,000 warrants sold at a combined USD 2.68, raising USD 938,000, with a USD 2.56 warrant exercise price. Each warrant adds a potential share, so the supply of stock can grow when holders exercise or resell. The placement lets investors demand repayment if shares are not trading on Nasdaq by October 31, 2026. The Nasdaq Hearings Panel approved continued listing on October 5, 2026, and trading resumed on October 7. Cash is not disclosed in the filing reviewed.

TNL Mediagene (NASDAQ:TNMG)

The catalyst label is a foreign issuer report: a 6-K dated October 16, 2026 citing a Nasdaq letter of October 14, 2026 that confirmed compliance with the USD 1.00 minimum bid rule. The stock opened 4.62% higher at USD 3.40 and then fell 5.06% from the open to USD 3.23, so buyers did not sustain the gap. Implied average volume is 1.20 million shares, own arithmetic, and turnover is USD 5.04 million, own arithmetic. Published market data lists 319,550 shares outstanding, which would put volume at 4.9 times the count, but the table market value of USD 2 million and that share count are not reconciled. The open risk is equity: the company must show USD 2.5 million of stockholders' equity by October 30, 2026 under Nasdaq Rule 5550(b)(1) and has warned it may not meet the deadline. Per the 6-K dated October 2, 2026, the Japanese business is to be sold for USD 5.5 million, with at least USD 4.5 million due at closing and a secured note maturing December 31, 2026.

ACV Auctions (NASDAQ:ACVA)

The table label reads News, and the news is the Copart agreement of September 10, 2026: USD 10.50 in cash per share, valuing ACV at USD 1.9 billion, with no financing condition. On October 16, 2026 intraday the stock printed 5,338,105 shares at USD 10.50, unchanged, with no gap and no move from the open. Volume of 1.3x implies a 4.11 million share average and an excess of 1.23 million shares, own arithmetic. A flat quote at the offer signals low perceived deal risk, because an all-cash tender caps upside at the offer. The structure needs a majority of shares tendered and expiry of the Hart-Scott-Rodino waiting period; untendered shares convert into the same USD 10.50 in a later merger. A completion 8-K or Form 25 notice was not located in the filings reviewed, so completion is not independently confirmed. If the deal failed, the USD 7.24 unaffected price implied by the 45% premium would be 31% below the offer, own arithmetic. Second quarter revenue was USD 214 million per the August 10, 2026 release.

Where Things Stand

Varonis (NASDAQ:VRNS) traded at 8.7 times normal volume because the October 15, 2026 Proofpoint offer of USD 49.75 in cash turned a growth stock into a spread trade, while SCWorx rose 56.72% on thin supply with no identified catalyst. Ranked by relative volume: Varonis 8.7x, SCWorx 1.9x, TNL Mediagene 1.3x, ACV Auctions 1.3x. Ranked by turnover as a share of market value, own arithmetic: SCWorx 379%, Varonis 12.2%, ACV Auctions (NASDAQ:ACVA) 3.1%; TNL Mediagene is excluded because its share count and market value are unreconciled. Next dated events are the October 30 and October 31 deadlines at the two microcaps and the Varonis proxy.